Clinical resources
Use these materials to familiarise yourself with information on Tavlesse. If you would like to download these resources, please contact us.
To view the abbreviated prescription information, click here.
Summary of product characteristics
For more information about Tavlesse 100 mg in England, Scotland or Wales, consult your local SmPC here.
Summary of product characteristics
For more information about Tavlesse 150 mg in England, Scotland or Wales, consult your local SmPC here.
Summary of product characteristics
For more information about Tavlesse in Northern Ireland, consult your local SmPC here.
Patient information leaflet
View the patient information leaflet here.
Tavlesse placebo-controlled trials (FIT-1 + FIT-2) in the American…
Request a copy of ‘Fostamatinib for the treatment of adults with persistent and chronic immune thromocytopenia: Results of two phase 3, randomised, placebo-controlled trial’ by Bussel et al. 2019 here.
Tavlesse open-label extension study (FIT-3) in the American Journal of…
Request a copy of 'Long-term Fostamatinib for the treatment of adults with immune thromocytopenia during the phase 3 clinical trial program’ by Bussel et al. 2018 here.
Newland & McDonald, 2020
Request a copy of 'Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia’ by Newland and McDonald here.